Business
Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025
LEXINGTON, Mass., August 19, 2025--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will host a virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET. The event will feature presentations from senior management and industry thought leaders, offering insights into transformative developments that could shape the future of cancer treatment. The agenda includes a strategic and financial overview, achievements tied to the Zydus partnershi
About this update from Agenus Inc.
[{"type":"text","content":"LEXINGTON, Mass., August 19, 2025--(BUSINESS WIRE)--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will host a virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET. The event will feature presentations from senior management and industry thought leaders, offering insights into transformative developments that could shape the future of cancer treatment. The agenda includes a strategic and financial overview, achievements tied to the Zydus partnership closing, patient needs fueling interest in colorectal cancer (CRC) studies, recent data from the botensilimab (BOT) and balstilimab (BAL) program, and an overview of the Phase 3 BATTMAN study in metastatic CRC—plus highlights of upcoming milestones and potential breakthroughs in immuno-oncology. The session will conclude with a live Q&A.","length":872,"tagName":"p"},{"type":"text","content":"Speakers to Include:","length":20,"tagName":"p"},{"type":"text","content":"Garo H. Armen, PhDFounder, Chairman, CEO of AgenusJennifer Buell, PhDCEO of MiNK Therapeutics/ Chair of Executive Committee of AgenusRichard M. Goldberg, MDChief Development Officer of Agenus (joined May 2025)GI oncology expert with 40+ years in CRC researchNicholas C. DeVito, MDAssistant Professor of Medical Oncology at Duke UniversityPrimarily treats patients with CRC and gastroesophageal cancersResearch focused on tumor immune evasion and immunotherapyChris O'Callaghan, DVM, MSc, PhD, & Jonathan Loree, MD, MS, FRCPC (CCTG):Senior Investigators at Canadian Cancer Trials Group (CCTG)","length":615,"tagName":"p","attribs":{}},{"type":"text","content":"Stakeholder Briefing Details:","length":29,"tagName":"p"},{"type":"text","content":"Webcast Link | https://events.q4inc.com/attendee/965806302","length":58,"tagName":"p"},{"type":"text","content":"Audience Conference Call Registration Link | https://registrations.events/direct/Q4I7324292","length":91,"tagName":"p"},{"type":"text","content":"Conference ID: 73242","length":20,"tagName":"p"},{"type":"text","content":"About Agenus","length":12,"tagName":"p"},{"type":"text","content":"Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cance...